These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 38001941)

  • 1. Iron Bioavailability in the Extracellular Environment Is More Relevant Than the Intracellular One in Viability and Gene Expression: A Lesson from Oligodendroglioma Cells.
    Braidotti S; Curci D; Zampieri D; Covino C; Zanon D; Maximova N; Sala R
    Biomedicines; 2023 Oct; 11(11):. PubMed ID: 38001941
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metastatic anaplastic oligodendroglioma simulating acute leukemia. A case report.
    Anand M; Kumar R; Jain P; Gupta R; Ghosal N; Sharma A; Agarwal A; Sharma MC
    Acta Cytol; 2003; 47(3):467-9. PubMed ID: 12789933
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Grading of oligodendroglioma in dogs based on magnetic resonance imaging.
    Amphimaque B; Durand A; Oevermann A; Vidondo B; Schweizer D
    J Vet Intern Med; 2022 Nov; 36(6):2104-2112. PubMed ID: 36366870
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 5. iTRAQ-based quantitative proteomic analysis for identification of oligodendroglioma biomarkers related with loss of heterozygosity on chromosomal arm 1p.
    Yang LS; Xu XE; Liu XP; Jin H; Chen ZQ; Liu XH; Wang Y; Huang FP; Shi Q
    J Proteomics; 2012 Dec; 77():480-91. PubMed ID: 23041135
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Codeletions at 1p and 19q predict a lower risk of pseudoprogression in oligodendrogliomas and mixed oligoastrocytomas.
    Lin AL; Liu J; Evans J; Leuthardt EC; Rich KM; Dacey RG; Dowling JL; Kim AH; Zipfel GJ; Grubb RL; Huang J; Robinson CG; Simpson JR; Linette GP; Chicoine MR; Tran DD
    Neuro Oncol; 2014 Jan; 16(1):123-30. PubMed ID: 24285548
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinicopathological features in the recurrence of oligodendroglioma and diffuse astrocytoma.
    Takeuchi H; Hosoda T; Kitai R; Kodera T; Arishima H; Tsunetoshi K; Neishi H; Yamauchi T; Sato K; Imamura Y; Itoh H; Kubota T; Kikuta K
    Brain Tumor Pathol; 2012 Jul; 29(3):140-7. PubMed ID: 22648019
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ethanol effect on cell proliferation in the human hepatoma HepaRG cell line: relationship with iron metabolism.
    Tuoi Do TH; Gaboriau F; Ropert M; Moirand R; Cannie I; Brissot P; Loréal O; Lescoat G
    Alcohol Clin Exp Res; 2011 Mar; 35(3):408-19. PubMed ID: 21143242
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular landscape of IDH-mutant astrocytoma and oligodendroglioma grade 2 indicate tumor purity as an underlying genomic factor.
    Zhao B; Xia Y; Yang F; Wang Y; Wang Y; Wang Y; Dai C; Wang Y; Ma W
    Mol Med; 2022 Mar; 28(1):34. PubMed ID: 35287567
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of newly diagnosed symptomatic pure low-grade oligodendrogliomas with PCV chemotherapy.
    Lebrun C; Fontaine D; Bourg V; Ramaioli A; Chanalet S; Vandenbos F; Lonjon M; Fauchon F; Paquis P; Frenay M
    Eur J Neurol; 2007 Apr; 14(4):391-8. PubMed ID: 17388986
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outcomes and Prognostic Factors in Pediatric Oligodendroglioma: A Population-Based Study.
    Goel NJ; Abdullah KG; Lang SS
    Pediatr Neurosurg; 2018; 53(1):24-35. PubMed ID: 29131101
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Conventional and advanced (DTI/SWI) neuroimaging findings in pediatric oligodendroglioma.
    Wagner MW; Poretti A; Huisman TA; Bosemani T
    Childs Nerv Syst; 2015 Jun; 31(6):885-91. PubMed ID: 25813856
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term temozolomide treatment induces marked amino metabolism modifications and an increase in TMZ sensitivity in Hs683 oligodendroglioma cells.
    Lamoral-Theys D; Le Mercier M; Le Calvé B; Rynkowski MA; Bruyère C; Decaestecker C; Haibe-Kains B; Bontempi G; Dubois J; Lefranc F; Kiss R
    Neoplasia; 2010 Jan; 12(1):69-79. PubMed ID: 20072655
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Classification of subpopulations of cells within human primary brain tumors by single cell gene expression profiling.
    Möllerström E; Rydenhag B; Andersson D; Lebkuechner I; Puschmann TB; Chen M; Wilhelmsson U; Ståhlberg A; Malmgren K; Pekny M
    Neurochem Res; 2015 Feb; 40(2):336-52. PubMed ID: 25249434
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bcl-2 promotes malignant progression in a PDGF-B-dependent murine model of oligodendroglioma.
    Doucette T; Yang Y; Zhang W; Fuller GN; Suki D; Fults DW; Rao G
    Int J Cancer; 2011 Nov; 129(9):2093-103. PubMed ID: 21171016
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intracellular Iron Chelation Modulates the Macrophage Iron Phenotype with Consequences on Tumor Progression.
    Mertens C; Akam EA; Rehwald C; Brüne B; Tomat E; Jung M
    PLoS One; 2016; 11(11):e0166164. PubMed ID: 27806101
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genomic alterations of oligodendrogliomas at distant recurrence.
    Liu G; Bu C; Guo G; Zhang Z; Sheng Z; Deng K; Wu S; Xu S; Bu Y; Gao Y; Wang M; Liu G; Kong L; Li T; Li M; Bu X
    Cancer Med; 2023 Aug; 12(16):17171-17183. PubMed ID: 37533228
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Brain and bone cancer targeting by a ferrofluid composed of superparamagnetic iron-oxide/silica/carbon nanoparticles (earthicles).
    Wu VM; Huynh E; Tang S; Uskoković V
    Acta Biomater; 2019 Apr; 88():422-447. PubMed ID: 30711662
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cyclin D1 and cdk4 mediate development of neurologically destructive oligodendroglioma.
    Ciznadija D; Liu Y; Pyonteck SM; Holland EC; Koff A
    Cancer Res; 2011 Oct; 71(19):6174-83. PubMed ID: 21844184
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictors of clinical outcome in pediatric oligodendroglioma: meta-analysis of individual patient data and multiple imputation.
    Wang KY; Vankov ER; Lin DDM
    J Neurosurg Pediatr; 2018 Feb; 21(2):153-163. PubMed ID: 29192869
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.